Menu

Patient Benefits Patient Benefits

Patient Benefits

What are the key considerations affecting inhaler choice, from a patient and physician perspective?

Quick links

Ease of Use

GO TO SECTION

Education

GO TO SECTION

Low patient error rate

GO TO SECTION

Single type of inhaler versus multiple inhaler types

GO TO SECTION

Patient Preference

GO TO SECTION

Clinical Efficacy

GO TO SECTION

Patient benefits: Summary

GO TO SECTION

Ease of use

Poor inhaler technique can lead to poor symptom control and increased unscheduled healthcare resource utilisation.1,2

Evolution of Accuhaler/Diskus to Ellipta: Technical advantages of the Ellipta inhaler

Continue or go back to the top

BACK TO TOP

Education

Education and teaching is essential as it ensure correct usage and can improve a patient’s inhaler technique.2,3

Time to be taught correct inhaler technique

Median time to demonstrate correct inhaler use in five sub-studies of commonly used respiratory inhalers.3,*

bar-graph-showing-the-median-training-time-to-demonstrate-correct-inhaler-use-of-commonly-used-respiratory-inhalers-in-5-sub-studies.-In-each-sub-study-the-median-training-time-was-significantly-shorter-with-the-Ellipta-inhaler-versus-the-comparator-inhaler

Adapted with permission from van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079 under a Creative Commons License (https://creativecommons.org/licenses/by/4.0).

*Median training time to demonstrate correct inhaler use, defined as the time from when the patient started to read the patient information leaflet until up to three healthcare provider instructions were given and the patient demonstrated corrected inhaler use.

Continue or go back to the top

BACK TO TOP

Low patient error rate

Inhaler errors are associated with worse outcomes.4,5

Critical errors after reading Patient Information Leaflets for commonly used inhalers

Percentage of patients with COPD making at least one critical error* after reading the patient information leaflet in five sub-studies of commonly used respiratory inhalers.3

*Critical error: defined as errors that are likely to result in no, or minimal, medication being inhaled.3

Continue or go back to the top

BACK TO TOP

Single type of inhaler versus multiple inhaler types

Delivering therapies via one inhaler rather than multiple inhaler types may be more convenient for patients.6 One of the determinants of poor inhaler technique is the use of multiple devices.2,7

Critical errors with a single inhaler versus multiple inhaler types for triple therapy

PREV
NEXT

Number of patients with ≥1 critical error using the Ellipta inhaler versus Diskus + Handihaler inhalers after reading the patient information leaflet.8

bar-graph-showing-the-proportion-of-patients-making-at-least-one-critical-error-after-reading-the-patient-information-leaflet.-The-proportion-of-patients-making-at-least-one-critical-error-was-9-percent-for-the-Ellipta-inhaler-versus-75-percent-for-Diskus-plus-Handihaler

Number of patients with ≥1 critical error using the Ellipta inhaler versus Turbuhaler + Handihaler inhalers after reading the patient information leaflet.8

bar-graph-showing-the-proportion-of-patients-making-at-least-one-critical-error-after-reading-the-patient-information-leaflet.-The-proportion-of-patients-making-at-least-one-critical-error-was-9-percent-for-the-Ellipta-inhaler-versus-73-percent-for-Turbuhaler-plus-Handihaler

Kaplan-Meier plot of total time taken to demonstrate correct inhaler use for a single inhaler versus two inhalers in a study evaluating the benefit of single inhaler compared with a combination of DPIs in patients with COPD (N=79).8

Kaplan-Meier-plot-of-the-total-time-taken-to-demonstrate-correct-inhaler-use-for-a-single-inhaler-versus-two-inhalers-indicating-patients-using-the-single-inhaler-take-less-time-to-demonstrate-correct-inhaler-use-versus-patients-using-two-inhalers

Adapted with permission from van der Palen J, Moeskops-van Beurden W, Dawson CM, et al. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2515-2523.

Continue or go back to the top

BACK TO TOP

Patient preference

Choice of inhaler should be tailored to a patient and take into account their preference.2,3

Patient inhaler preference

Preference for inhaler devices in five sub-studies of commonly used respiratory inhalers.3

bar-graph-showing-preference-for-inhaler-devices-in-five-sub-studies-of-commonly-used-respiratory-inhalers.-In-each-sub-study,-there-was-a-greater-proportion-of-patients-that-preferred-Ellipta-over-other-commonly-used-respiratory-inhalers

Adapted with permission from van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079 under a Creative Commons License (https://creativecommons.org/licenses/by/4.0).

Continue or go back to the top

BACK TO TOP

Clinical efficacy

Inhaled therapy delivered via the Ellipta inhaler provides benefits across multiple outcomes including lung function, symptoms and exacerbations.

Exacerbations

Find out more

Lung function

Find out more

Symptoms

Find out more

Switching from MITT to FF/UMEC/VI

Find out more

Continue or go back to the top

BACK TO TOP

Patient benefits: Summary

  • Poor inhaler technique can lead to poor symptom control and increased unscheduled healthcare resource utilisation.1,2
  • Choice of inhaler should be tailored to a patient and take into account their preference and technique.2,3
  • The Ellipta inhaler is easy to use and results in fewer patients making critical errors compared with other commonly used inhalers.3,9

Continue your journey

Unmet need teaser

Unmet need

Explore the unmet need of inhaler therapy

GO TO UNMET NEED

Technical performance teaser

Technical performance

Explore the technical performance of inhalers

GO TO TECHNICAL PERFORMANCE

Abbreviations

COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FF, fluticasone furoate; MDI, metered dose inhaler; MITT, multiple inhaler triple therapy; UMEC, umeclidinium; VI, vilanterol.

Ellipta, Accuhaler and Diskus are owned by or licensed to the GSK Group of Companies. HandiHaler is a registered trademark of Boehringer Ingelheim International GmbH. Turbuhaler is a registered trademark of AstraZeneca. Breezhaler is a registered trademark of Novartis AG.

References

  1. Melani AS, Bonavia M, Cilenti V, et al. Respir Med. 2011;105:930-938.
  2. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2022. Available at: https://goldcopd.org/2022-gold-reports/ Accessed December 2021.
  3. van der Palen J, Thomas M, Chrystyn H, et al. NPJ Prim Care Respir Med. 2016;26:16079.
  4. Molimard M, Raherison C, Lignot S, et al. Eur Respir J. 2017;49:1601794.
  5. Usmani OS, Lavorini F, Marshall J, et al. Respir Res. 2018;19:10.
  6. Grant AC, Walker R, Hamilton M, Garrill K. J Aerosol Med Pulm Drug Deliv. 2015;28:474-485.
  7. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. Int J Chron Obstruct Pulmon Dis. 2017;12:59-71.
  8. van der Palen J, Moeskops-van Beurden W, Dawson CM, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:2515-2523.
  9. Collier DJ, Wielders P, van der Palen J, et al. Int J Chron Obstruct Pulmon Dis. 2020;15:1301-1313.

© 2022 GSK group of companies or its licensor. Trademarks are owned by or licensed to the GSK group of companies.

NX-GBL-UCV-WCNT-220005 | Date of preparation: August 2022